Foundayo for Overweight: Who Is Eligible in the UK?

Foundayo is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 30 alongside a weight related health condition, used with a reduced calorie diet and increased physical activity.

That sentence answers the search, and pages on this topic tend to stop there. The trouble is that it describes the doorway rather than the corridor. BMI gets you to an assessment. It does not get you a prescription, and a significant number of people who clear the BMI threshold are not supplied this medicine.

Key things to know

• Foundayo is the brand name for orforglipron, licensed by the MHRA on 10 August 2026 for weight management in adults.
• The licensed criteria are a BMI of 30 or above, or 27 to 30 with a weight related health condition, alongside diet and activity changes.
• NICE uses lower BMI thresholds when assessing overweight, obesity and cardiometabolic risk in certain ethnic groups. These NICE thresholds should not be confused with the BMI thresholds in Foundayo's marketing authorisation.
• NICE recommends using waist-to-height ratio in adults with a BMI below 35. A ratio of 0.5 or above indicates increased central adiposity, while 0.6 or above indicates higher central adiposity.
• BMI is the entry criterion, not the decision. Medical history, current medicines and pregnancy status all sit after it.
• Some people are not suitable at any BMI, including anyone pregnant, trying to conceive or breastfeeding.
• A consultation that cannot decline you is not an assessment.
• Treatment suitability depends on an individual clinical assessment.

The licensed criteria in one place

Foundayo is also licensed separately for blood glucose control in adults with type 2 diabetes that is not adequately controlled. It is a GLP-1 receptor agonist within the wider GLP-1 and GLP-1 receptor medicine class designed to treat obesity, overweight status, and type 2 diabetes, and in its diabetes indication it helps stabilize and regulate blood sugar levels, which is a different use prescribed as part of diabetes care rather than as weight management.

The diet and activity requirement is part of the licence, not a suggestion attached to it. The trial results were produced by people who took the medicine and changed how they ate and moved. A service that treats those changes as optional is working outside the terms the medicine was licensed under.

Why BMI alone does not settle it

BMI is your weight in kilograms divided by the square of your height in metres. Someone 1.70m and 87kg is around 30.1. The same height at 80kg is around 27.7.

It is a useful screening number and a blunt one. It does not distinguish muscle from fat, so a heavily muscled person can read high without carrying excess body weight. It says nothing about where weight sits on the body, which matters, because weight carried around the middle carries different risks from the same weight carried elsewhere. This central weight distribution is linked to increased risk of cardiovascular disease and obstructive sleep apnoea, both serious health concerns. Additionally, body mass index alone cannot predict complications such as severe stomach pain or difficulty breathing that may arise from excess weight.

Lower thresholds for some family backgrounds

This is the eligibility point that changes the answer for a large number of people in the UK, and it rarely appears on pages about weight management treatment.

NICE recommends using lower BMI thresholds for overweight and obesity for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds. The reason is that increased cardiometabolic health risk appears at a lower BMI in these groups, so the standard thresholds understate the risk.

In practice this means a reading you have dismissed as borderline may not be borderline for you. If your family background is one of those listed, raise it at your consultation rather than assuming the general figures apply. Your prescriber applies the adjustment, and it is a clinical judgement rather than something to calculate yourself.

Waist to height ratio, the measure you can take yourself

NICE recommends using waist-to-height ratio in adults with a BMI below 35. A ratio of 0.5 or above indicates increased central adiposity, while 0.6 or above indicates higher central adiposity. A simple rule of thumb is to aim for a waist less than half your height.

It takes a tape measure and half a minute. Measure your waist at the midpoint between the bottom of your ribs and the top of your hip bones, standing, breathing out normally, tape snug but not compressing. Then compare it with half your height. Someone 170cm tall is looking for a waist below 85cm.

A waist above half your height points to weight carried centrally, which is associated with greater health risk than the BMI alone suggests. It is not itself a licensing criterion for Foundayo, so it will not move you across the BMI threshold. What it does is tell you, and your prescriber, something about risk that BMI misses, and it is worth bringing to a consultation.

What counts as a weight related condition

For anyone with a BMI between 27 and 30, this is the question that decides eligibility.

The product information gives examples rather than an exhaustive list. Your prescriber decides whether your particular condition meets the clinical requirements for treatment.

A condition you suspect but have never had confirmed does not count in the same way as one that is diagnosed and documented. If you think you have sleep apnoea and have never been assessed, that is worth pursuing in its own right rather than presenting as a qualifying condition.

And a condition being managed well still counts. Treated high blood pressure is still high blood pressure. People sometimes leave it off a form because it is controlled, which is exactly the wrong instinct.

The six gates of a Foundayo assessment

A clinical assessment will usually consider several areas before a prescriber decides whether Foundayo is appropriate.

Gate one: your measurements

Height, weight and the BMI that comes from them, with the adjustments described above where they apply. Give accurate figures. Inflating a weight to clear a threshold puts you on a medicine that was not assessed as appropriate for you, which is not a win.

Gate two: a weight related condition, if you need one

Only relevant if your BMI is between 27 and 30. Name the condition, say when it was diagnosed and by whom, and say how it is currently managed.

Gate three: medical history

Your medical history is an important part of the assessment because some conditions may require extra caution, monitoring or a different treatment approach.

Your prescriber will ask about previous pancreatitis because orforglipron has not been studied in people with a history of pancreatitis and should be used with caution in this group. They may also ask about gallbladder problems, liver and kidney health, digestive conditions, diabetes and the medicines you take. Severe liver impairment and severe gastrointestinal conditions, including severe gastroparesis, are particularly relevant when deciding whether Foundayo is appropriate.

Your prescriber may also ask about your eating patterns, any history of disordered eating, pregnancy plans and other aspects of your health that could affect treatment or how safely it can be used.

These questions are not simply part of a checklist. They help your prescriber understand your individual risks and decide whether Foundayo is suitable for you.

Gastrointestinal side effects are among the most common adverse effects reported with orforglipron. In clinical studies, nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain were reported very commonly. Nausea, vomiting and diarrhoea were more frequent during dose escalation and generally decreased over time.

Answer the questions as fully and honestly as you can. Your prescriber can only take a condition, medicine or previous reaction into account if they know about it. If something in your medical history is relevant, it is safer to mention it than to assume it does not matter.

Gate four: everything you take

List every medicine, including anything bought without a prescription, anything prescribed by someone else, and supplements.

Foundayo can be taken once daily at any time of day without food or water restrictions. Because orforglipron delays gastric emptying, it may affect the absorption of some oral medicines, so your prescriber should know about everything you take.

Gate five: pregnancy, conception and breastfeeding

Foundayo should not be used during pregnancy or breastfeeding. If you are planning a pregnancy, speak to your prescriber because treatment should be stopped at least 3 weeks before a planned pregnancy.

Gate six: diet and activity

The licence covers use alongside a reduced calorie diet and increased physical activity, so a proper assessment asks what you currently do and what you are prepared to change.

This is not a test with a right answer. It is a check that you understand what you are agreeing to, because the medicine was studied and licensed as part of a package rather than on its own.

Who cannot be prescribed Foundayo

Foundayo is not suitable for everyone. The prescriber will consider your medical history, current medicines, pregnancy status and other clinical factors before prescribing.

It should not be used in people with a known hypersensitivity to orforglipron or any of its ingredients. It is not recommended during pregnancy or breastfeeding, and it should be discontinued at least 3 weeks before a planned pregnancy. People with a history of pancreatitis require particular caution, while severe hepatic impairment is a reason for Foundayo not to be recommended.

Foundayo is a prescription-only medicine in the UK. Whether it is available through a particular NHS service or privately depends on local prescribing and commissioning arrangements.

What happens if you are declined

If you are declined, ask the prescriber to explain the reason. It may relate to your medical history, another medicine, pregnancy plans, your measurements or another clinical consideration. Understanding the reason helps you know whether anything needs investigating or reviewing before another treatment is considered.

Temporary and ongoing reasons for not starting Foundayo

The reason a prescriber recommends against Foundayo matters is because some situations can be reviewed or addressed, while others may require a different treatment approach.

Sometimes the decision is based on something that needs further assessment first. This might include a medicine that needs reviewing, a health condition that needs to be confirmed or stabilised, measurements that need to be repeated, or a pregnancy or planned pregnancy that changes whether treatment is appropriate. In these situations, the next step is usually to address the specific issue and then discuss treatment again with your prescriber.

Other situations may make Foundayo inappropriate or require particular caution. For example, people with a history of pancreatitis need careful assessment because orforglipron has not been studied in this group and the UK product information recommends caution. Severe hepatic impairment is another situation in which orforglipron is not recommended. These are clinical decisions rather than simple yes-or-no rules, so the reason for the decision matters.

If Foundayo is not appropriate for you, the useful next question is what treatment or weight-management approach would be suitable instead. A discussion with your prescriber can help clarify why Foundayo was not recommended and what your alternatives are.

What eligibility does not tell you

Clearing every gate tells you that treatment can be prescribed. It does not tell you what will happen next.

In the phase 3 programme over 72 weeks, average weight loss with the highest dose was 12.4% of starting body weight, versus around 2.1% on placebo, which is considered meaningful weight loss in this setting. Averages sit in the middle of a spread, so some people in those trials lost considerably more and some considerably less. Results vary between individuals, and no eligibility criterion predicts where you will fall.

Foundayo is a once-daily tablet containing orforglipron, and the licensed Foundayo dose is taken at any time of day, with no requirement to time it around food or water. It mimics GLP-1 to reduce appetite and slow digestion, so people commonly describe feeling full sooner and thinking about food less.

Orforglipron is a GLP-1 receptor agonist that influences appetite and food intake and also delays gastric emptying. Digestive side effects are the common ones, particularly at the start and after each dose increase. Some people discontinue treatment because of gastrointestinal side effects, particularly during dose escalation. The exact rate varies by study, dose and population.

Medical Disclaimer

This article is general information about prescription only medicine and is not medical advice. It does not replace an assessment by a qualified healthcare professional who knows your medical history, and it cannot tell you whether you personally will be prescribed this treatment. Foundayo should only be used under the supervision of an appropriately qualified prescriber, and results vary between individuals.

Always read the patient information leaflet supplied with your medicine and follow the advice your prescriber gives you. Tell your prescriber about every medicine and supplement you take, and about any history of pancreatitis, thyroid conditions, or pregnancy and breastfeeding. Suspected side effects can be reported through the MHRA Yellow Card scheme.